An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.
An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.
A one year extension study using flexible doses, 20 or 30 mg daily, of open-label bifeprunox.
Inclusion Criteria:
Exclusion Criteria:
Boynton Beach, California 33426, United States
Coevr d'Alene, Idaho 83814, United States
Indiannapolis, Indiana 46202, United States